Chemotherapy and Targeted Therapy

Roche Deepens Strategic Ties with China’s Hansoh Pharma in Landmark $400M ADC Partnership

• Chemotherapy and Targeted Therapy

Roche Deepens Strategic Ties with China’s Hansoh Pharma in Landmark $400M ADC Partnership

Raul Delapena Setiawan October 20, 2026

In a move that underscores the shifting geography of pharmaceutical innovation, Swiss healthcare giant Roche has announced...

Read More Read more about Roche Deepens Strategic Ties with China’s Hansoh Pharma in Landmark $400M ADC Partnership

A Second Chance at Sunlight: Disc Medicine’s Bitopertin Poised for FDA Redemption

• Chemotherapy and Targeted Therapy

A Second Chance at Sunlight: Disc Medicine’s Bitopertin Poised for FDA Redemption

Reynand Wu October 20, 2026

In the high-stakes world of biotechnology, few narratives are as compelling as the journey from regulatory rejection...

Read More Read more about A Second Chance at Sunlight: Disc Medicine’s Bitopertin Poised for FDA Redemption

Roche Deepens Ties with Chinese Biotech: A Strategic Pivot in Cancer Drug Discovery

• Chemotherapy and Targeted Therapy

Roche Deepens Ties with Chinese Biotech: A Strategic Pivot in Cancer Drug Discovery

Jia Lissa October 20, 2026

In a significant reinforcement of its global oncology pipeline, Roche has entered into a substantial new partnership...

Read More Read more about Roche Deepens Ties with Chinese Biotech: A Strategic Pivot in Cancer Drug Discovery

FDA Launches Ambitious "Rare Disease Framework Initiative" to Standardize Drug Approval Pathways

• Chemotherapy and Targeted Therapy

FDA Launches Ambitious "Rare Disease Framework Initiative" to Standardize Drug Approval Pathways

Rifan Muazin October 19, 2026

In a significant move to overhaul the regulatory landscape for orphan drug development, the U.S. Food and...

Read More Read more about FDA Launches Ambitious "Rare Disease Framework Initiative" to Standardize Drug Approval Pathways

Bridging the Gap: Can Iambic Therapeutics Succeed Where Other AI Drug Developers Have Faltered?

• Chemotherapy and Targeted Therapy

Bridging the Gap: Can Iambic Therapeutics Succeed Where Other AI Drug Developers Have Faltered?

Lina Hope October 19, 2026

The intersection of artificial intelligence and pharmaceutical development has long been framed as the next great frontier...

Read More Read more about Bridging the Gap: Can Iambic Therapeutics Succeed Where Other AI Drug Developers Have Faltered?

FDA Launches Ambitious "Rare Disease Framework Initiative" to Standardize Drug Approval Pathways

• Chemotherapy and Targeted Therapy

FDA Launches Ambitious "Rare Disease Framework Initiative" to Standardize Drug Approval Pathways

Dwi Wanna October 19, 2026

In a significant move to overhaul the regulatory landscape for orphan drug development, the U.S. Food and...

Read More Read more about FDA Launches Ambitious "Rare Disease Framework Initiative" to Standardize Drug Approval Pathways

Bridging the Gap: Can Iambic Therapeutics Succeed Where Other AI Drug Developers Have Faltered?

• Chemotherapy and Targeted Therapy

Bridging the Gap: Can Iambic Therapeutics Succeed Where Other AI Drug Developers Have Faltered?

Pevita Pearce October 18, 2026

The intersection of artificial intelligence and pharmaceutical development has long been framed as the next frontier of...

Read More Read more about Bridging the Gap: Can Iambic Therapeutics Succeed Where Other AI Drug Developers Have Faltered?

FDA Launches Ambitious ‘Rare Disease Framework Initiative’ to Standardize Drug Approval Pathways

• Chemotherapy and Targeted Therapy

FDA Launches Ambitious ‘Rare Disease Framework Initiative’ to Standardize Drug Approval Pathways

Raul Delapena Setiawan October 18, 2026

In a move signaling a major shift in how the U.S. regulatory body evaluates life-saving treatments, the...

Read More Read more about FDA Launches Ambitious ‘Rare Disease Framework Initiative’ to Standardize Drug Approval Pathways

Bridging the Gap: Can Iambic Therapeutics Succeed Where Other AI Drug Developers Have Stumbled?

• Chemotherapy and Targeted Therapy

Bridging the Gap: Can Iambic Therapeutics Succeed Where Other AI Drug Developers Have Stumbled?

Lina Hope October 18, 2026

The promise of artificial intelligence in drug discovery has long been one of the most seductive narratives...

Read More Read more about Bridging the Gap: Can Iambic Therapeutics Succeed Where Other AI Drug Developers Have Stumbled?

Navigating the Orphan Frontier: The FDA’s Ambitious New Rare Disease Framework Initiative

• Chemotherapy and Targeted Therapy

Navigating the Orphan Frontier: The FDA’s Ambitious New Rare Disease Framework Initiative

Layla Zulfa October 18, 2026

In a landmark shift aimed at modernizing the regulatory landscape for orphan drug development, the U.S. Food...

Read More Read more about Navigating the Orphan Frontier: The FDA’s Ambitious New Rare Disease Framework Initiative